181 related articles for article (PubMed ID: 18776927)
1. The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT.
Luo XH; Chang YJ; Xu LP; Liu DH; Liu KY; Huang XJ
Bone Marrow Transplant; 2009 Jan; 43(1):29-36. PubMed ID: 18776927
[TBL] [Abstract][Full Text] [Related]
2. High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia.
Xu LP; Luo XH; Chang YJ; Liu DH; Liu KY; Chen YH; Huang XJ
Ann Hematol; 2009 Oct; 88(10):1015-24. PubMed ID: 19319533
[TBL] [Abstract][Full Text] [Related]
3. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
4. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
5. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
6. The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis.
Xu LP; Liu KY; Liu DH; Chen H; Han W; Chen YH; Wang Y; Huang XJ
Bone Marrow Transplant; 2010 Jun; 45(6):985-92. PubMed ID: 19898505
[TBL] [Abstract][Full Text] [Related]
7. Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors.
Zhao XY; Chang YJ; Xu LP; Liu DH; Liu KY; Huang XJ
Bone Marrow Transplant; 2009 Dec; 44(11):721-8. PubMed ID: 19377516
[TBL] [Abstract][Full Text] [Related]
8. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
[TBL] [Abstract][Full Text] [Related]
9. Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status.
Chang YJ; Xu LP; Liu DH; Liu KY; Han W; Chen YH; Yu-Wang ; Chen H; Wang JZ; Zhang XH; Zhao XY; Huang XJ
Biol Blood Marrow Transplant; 2009 May; 15(5):632-8. PubMed ID: 19361756
[TBL] [Abstract][Full Text] [Related]
10. [The impact of CD34(+) cells and T cells subsets in grafts on prognosis of HLA-identical sibling allogeneic peripheral blood stem cell transplantation].
Zhou Z; Wang M; He Y
Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):819-23. PubMed ID: 19176036
[TBL] [Abstract][Full Text] [Related]
11. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors.
Yamasaki S; Henzan H; Ohno Y; Yamanaka T; Iino T; Itou Y; Kuroiwa M; Maeda M; Kawano N; Kinukawa N; Miyamoto T; Nagafuji K; Shimoda K; Inaba S; Hayashi S; Taniguchi S; Shibuya T; Gondo H; Otsuka T; Harada M;
Bone Marrow Transplant; 2003 Sep; 32(5):505-10. PubMed ID: 12942097
[TBL] [Abstract][Full Text] [Related]
12. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Wang JZ; Gao ZY; Zhang YC; Jiang Q; Shi HX; Lu DP
Bone Marrow Transplant; 2006 Aug; 38(4):291-7. PubMed ID: 16883312
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic peripheral blood stem cell transplantation from two- or three-loci-mismatched related donors in adult Japanese patients with high-risk hematologic malignancies.
Yamasaki S; Ohno Y; Taniguchi S; Yoshida T; Hayashi S; Ogawa H; Shimazaki C; Takahashi S; Kasai M; Wake A; Nishimura M; Tokunaga K; Gondo H; Takaue Y; Harada M; Mineishi S;
Bone Marrow Transplant; 2004 Feb; 33(3):279-89. PubMed ID: 14647250
[TBL] [Abstract][Full Text] [Related]
14. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies.
Cao TM; Wong RM; Sheehan K; Laport GG; Stockerl-Goldstein KE; Johnston LJ; Shizuru JA; Negrin RS; Lowsky R
Exp Hematol; 2005 Mar; 33(3):279-85. PubMed ID: 15730851
[TBL] [Abstract][Full Text] [Related]
15. Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation.
Kim DH; Won DI; Lee NY; Sohn SK; Suh JS; Lee KB
Biol Blood Marrow Transplant; 2006 Jul; 12(7):719-28. PubMed ID: 16785061
[TBL] [Abstract][Full Text] [Related]
16. HLA-haploidentical blood and bone marrow transplantation with anti-thymocyte globulin: long-term comparison with HLA-identical sibling transplantation.
Chen XH; Gao L; Zhang X; Gao L; Zhang C; Kong PY; Liu H; Peng XG; Sun AH; Qi DG; Gong Y; Wang QY
Blood Cells Mol Dis; 2009; 43(1):98-104. PubMed ID: 19356956
[TBL] [Abstract][Full Text] [Related]
17. IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation.
Zhao XY; Xu LL; Lu SY; Huang XJ
Eur J Immunol; 2011 Feb; 41(2):514-26. PubMed ID: 21268020
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation.
Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; García-Latorre E; Moreno-Lafont M; Estrada-García I; Montiel-Cervantes L; Tripp-Villanueva F; Ayala-Sánchez M; García-León LD; Borbolla-Escoboza JR; Mayani H
Ann Hematol; 2006 Feb; 85(2):113-20. PubMed ID: 16311734
[TBL] [Abstract][Full Text] [Related]
19. [Effects of graft compositions on hematopoietic reconstitution and graft-versus-host disease in related donor peripheral blood stem cell transplantation].
Zhan Y; Yi ZS; Wei YQ; Huang F; Zhang YM; Fan ZP; Feng R
Zhonghua Xue Ye Xue Za Zhi; 2008 May; 29(5):333-6. PubMed ID: 18844073
[TBL] [Abstract][Full Text] [Related]
20. Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.
Kanate AS; Craig M; Cumpston A; Saad A; Hobbs G; Leadmon S; Bunner P; Watkins K; Bulian D; Gibson L; Abraham J; Remick SC; Hamadani M
Hematol Oncol Stem Cell Ther; 2011; 4(4):149-56. PubMed ID: 22198185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
